Infinity Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Infinity Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Infinity Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.
Infinity Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer of the Prostate, with 1 trials.
Top-decile sponsor footprint
Infinity Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
NCT03980041
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
NCT01609179
A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
NCT01371617
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
NCT01427946
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01362400
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
NCT01310816
Dose Escalation of IPI-493 in Hematologic Malignancies
NCT01193491
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
NCT01130142
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
NCT00817362
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
NCT00761696
A Phase 1 Dose Escalation Study of IPI-493
NCT00724425
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
NCT00627419
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
NCT00606814
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
NCT00564928
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT00431015
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
NCT00276302
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
NCT00113204
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
Therapeutic Areas
How the Infinity Pharmaceuticals early-phase archive is shaped
17 indexed studies, none listed as recruiting (0% open); 13 completed (76%).
Phase mix: 0 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Cancer of the Prostate (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Infinity Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Infinity Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Infinity Pharmaceuticals page
17 registered trials is a research-attention snapshot, not an endorsement of Infinity Pharmaceuticals or any single study.
- None of Infinity Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cancer of the Prostate is the condition Infinity Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer of the Prostate trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Infinity Pharmaceuticals pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.